Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Feb 19, 2008 1:24 PM Flag

    THLD AND NSTR

    I was commenting in general on his investment targets, and while I have a small position in THLD and hope they are able to survive and realize the potential value from their pipeline, it is longshot. As you indicated, there is a "possible" partnership for Glufo, but the clinical results cannot be considered "robust" and if some company is interested in pursuing the hypoxia angle, why would they invest in Glufo, when TH-302 appears to have much more potential (based on the pre-clinical data). In other words, I believe there is value in the pipeline, but the company doesn't have enough cash to realize that value in the clinic and they don't have the leverage to negotiate a valuable (i.e. substantial up-front money)partnership on Glufo, so the most likely scenario is a buyout. The question is whether they can generate any meaningful clincal data on TH-302 before they put the company on the block?

 
THLD
0.3402-0.0638(-15.79%)May 6 4:00 PMEDT